Please login to the form below

Not currently logged in
Email:
Password:

CC-486

This page shows the latest CC-486 news and features for those working in and with pharma, biotech and healthcare.

BMS’ oral maintenance therapy boosts survival in AML patients

BMS’ oral maintenance therapy boosts survival in AML patients

We now look forward to taking the next steps to bring CC-486 to eligible AML patients in need,” he added. ... According to a statement issued by BMS, regulatory submissions for CC-486 are planned for the first half of 2020.

Latest news

  • Celgene’s ‘oral Vidaza’ clears phase 3 leukaemia trial Celgene’s ‘oral Vidaza’ clears phase 3 leukaemia trial

    The formulation – known as CC-486 – is an orally-active version of Vidaza, Celgene’s already-marketed azacitidine product which is administered intravenously. ... The new  QUAZAR AML-001 study compared CC-486 to placebo as a maintenance therapy

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Envision Pharma Group

We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....